US Patent

US9701636 — Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Composition of Matter · Assigned to Akebia Therapeutics Inc · Expires 2034-11-14 · 8y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects solid forms of the molecule {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid and methods for making and using them.

USPTO Abstract

Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.

Drugs covered by this patent

Patent Metadata

Patent number
US9701636
Jurisdiction
US
Classification
Composition of Matter
Expires
2034-11-14
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Akebia Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.